THORACIC MALIGNANCIES: 2018 INSIGHTS
Tirano (SO) 3 marzo 2018 PROGRAMMA SCIENTIFICO
8.30 Registration
First session - Immunopathology Chair: Silvio Veronese, Paolo Declich
Predictive factors for IO: PDL1 IHC vs TMB vs PDL1 IHC+TMB
9.00 Pathologist perspective Umberto Malapelle
9.15 Oncologist perspective Luca Toschi
9.30 Discussion
Second Session - Immunotherapy and its role in “early” and “late” stage NSCLC Chair: Paolo Bidoli, Mauro Palazzi, Gerolamo Rossi
9.45 The Ios indication in advanced NSCLC: perspective?
Francesco Grossi
IO in neo/adjuvant setting: wath is its role
10.00 Surgeon perspective Luca Bertolaccini
10.15 Oncologist perspective Alessandra Bearz
10.30 Combining radiotherapy with immune-checkpoint inhibitors: safety and activity
Davide Franceschini 10.45 Discussion
Third Session - Oncogene addiction: therapeutic strategy Chair: Nicoletta Zilembo, Adolfo Favaretto
11.00 EGFR: sequence or third gen TKIs up front Marcello Tiseo
11.15 ALK: sequence or second/third gen TKIs up front Enrica Capelletto
11.30 Discussion
Other OMAs: NGS discovery and its impact in clinical practice Coordinator: Vanesa Gregorc
11.45 Pros
Angelo Delmonte
12.00 Contra
Martina Imbimbo 12.15 Discussion
Point of view
The tumor, the host and their links Diego Cortinovis
Discussion: Roberta Buosi 13.00 Lunch
Fourth Session - MPM and other issues Chair: Alessandro Del Conte
MPM new avenues understanding the biology Coordinator Discussant: Giovanni Luca Ceresoli
14.00 Molecular targets Giulio Cerea
14.15 Immunotherapy Matteo Brighenti 14.30 Discussion
The adverse events of active treatments
14.45 Opioids AEs: practical management Raffaele Giusti
15.00 Lung toxicity: its impact and clinical relevance Clelia Casartelli
15.15 Financial toxicity: true sustainability Alessandro Follador
15.30 Discussion and closing remarks
SCIENTIFIC BOARD
Enrica Capelletto - A.O.U. San Luigi Gonzaga, Orbassano (TO) Diego Cortinovis - A.O. S. Gerardo, Monza (MB)
Marcello Tiseo - A.O.U. Parma
Giuseppe Valmadre - ASST Valtellina e Alto Lario
FACULTY
Alessandra Bearz - Centro di Riferimento Oncologico, Aviano (PN) Luca Bertolaccini - AUSL Romagna, Ravenna
Paolo Bidoli - A.O. S. Gerardo, Monza (MB)
Matteo Brighenti - A.O. Istituti Ospitalieri, Cremona
Roberta Buosi - Ospedale Santo Spirito, Casale Monferrato (AL) Enrica Capelletto - A.O.U. San Luigi Gonzaga, Orbassano (TO) Clelia Casartelli - Ospedale Valduce, Como
Giulio Cerea - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano
Giovanni Luca Ceresoli - Humanitas Gavazzeni, Bergamo Diego Cortinovis - A.O. S. Gerardo, Monza (MB)
Paolo Declich - ASST Valtellina e Alto Lario
Alessandro Del Conte - ASS 5 - Friuli Occidentale - P.O. di Pordenone
Angelo Delmonte - IRCCS-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC)
Adolfo Favaretto - Azienda ULSS 9 Treviso
Alessandro Follador – A.O.U. S. M. Misericordia, Udine
Davide Franceschini - Istituto Clinico Humanitas-Humanitas Cancer Center, Rozzano (MI)
Raffaele Giusti – A.O. Sant’Andrea, Roma
Vanesa Gregorc – Ospedale San Raffaele, Milano
Francesco Grossi - IRCCS AOU San Martino IST – Istituto Nazionale per la Ricerca sul Cancro, Genova
Martina Imbimbo - Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Umberto Malapelle - Azienda Universitaria Policlinico-Università degli Studi di Napoli Federico II, Napoli
Mauro Palazzi - ASST-Grande Ospedale Metropolitano Niguarda, Milano Gerolamo Rossi - Ospedale Valduce, Como
Marcello Tiseo - A.O.U. Parma
Luca Toschi - Istituto Clinico Humanitas-Humanitas Cancer Center, Rozzano (MI) Silvio Veronese - ASST-Grande Ospedale Metropolitano Niguarda, Milano
Nicoletta Zilembo - Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milano
